Journal Article

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Latini, Luciano, Crinò, Lucio, Giovanardi, Filippo, Romagnoli, Emanuela, Cazzaniga, Marina Elena, Michelotti, Andrea, Mattioli, Rodolfo, Riccardi, Ferdinando, Bria, Emilio, Sarobba, Giuseppina, Del Mastro, Lucia, Spazzapan, Simon, Marchetti, Paolo, Bisagni, Giancarlo, Turletti, Anna, Mustacchi, Giorgio, Giordano, Monica, De Laurentiis, Michelino, Montemurro, Filippo, Ricciardi, Giuseppina, Tonini, Giuseppe, Amoroso, Domenico, De Placido, Sabino, Livi, Lorenzo, Zambelli, Alberto, Ferraù, Francesco, Cognetti, Francesco, Bernardo, Antonio, Gamucci, Teresa, Garrone, Ornella, Giotta, Francesco, Biganzoli, Laura, Forcignanò, Rosachiara, Gennari, Alessandra, Pronzato, Paolo, Beano, Alessandra, Tagliaferri, Pierosandro, Putzu, Carlo, Blasi, Livio, Tinari, Nicola, Foladore, Silva, Verusio, Claudio

2023

Overview

GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.

• Publisher: MDPI AG,MDPI
• Subject: Antimitotic agents / Antineoplastic agents / Bevacizumab / Breast cancer / Cancer / Cancer therapies / Care and treatment / Chemotherapy / Clinical outcomes / Cohort analysis / ErbB-2 protein / Metastases / Metastasis / Oncology, Experimental / Patient outcomes / Patients / Taxanes / Tumors